ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

CARM Carisma Therapeutics Inc

1,29
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 11:03:09
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Carisma Therapeutics Inc CARM NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 1,29 11:03:09
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,29
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
29.5.202401:39EDGAR2Form SC 13D/A - General statement of acquisition of..
16.5.202413:30PRNUSCarisma Therapeutics Announces First Patient Dosed in Phase..
09.5.202413:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202413:41EDGAR2Form 8-K - Current report
09.5.202413:30PRNUSCarisma Therapeutics Reports First Quarter 2024 Financial..
08.5.202417:45BWCarmila: Réduction des moyens du contrat de liquidité
08.5.202413:30PRNUSCarisma Therapeutics Presents Preclinical Proof of Concept..
07.5.202417:45BWCARMILA: Information Concerning the Total Number of Voting..
06.5.202413:30PRNUSCarisma Therapeutics to Participate in The Citizens JMP Life..
02.5.202413:30PRNUSCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief..
24.4.202423:05PRNUSCarisma Therapeutics Announces Upcoming Presentation at the..
24.4.202418:43BWCarmila : Lancement d’un programme de rachat d’actions pour..
22.4.202422:35PRNUSCarisma Therapeutics to Present New Data at the American..
17.4.202417:45BWCarmila: First-quarter 2024 Financial Information
05.4.202417:45BWCarmila : Informations relatives au nombre total de droits..
03.4.202413:00PRNUSCarisma Therapeutics to Present at Upcoming Conferences
01.4.202414:35PRNUSCarisma Therapeutics Provides Business Update and Reports..
01.4.202413:00PRNUSCarisma Therapeutics Announces Changes to its Board of..
21.3.202422:00PRNUSCarisma Announces Upcoming Presentations at the American..
15.3.202417:45BWCARMILA : INFORMATION RELATIVE A LA REMUNERATION DES..
08.3.202417:45BWCORRIGE ET REMPLACE : Carmila : Evolution de la composition..
07.3.202422:05EDGAR2Form SC 13D/A - General statement of acquisition of..
07.3.202419:13BWCARMILA : Evolution de la composition du Conseil..
04.3.202417:45BWCarmila: Information Concerning the Total Number of Voting..
28.2.202413:30PRNUSCarisma Therapeutics to Participate in TD Cowen's 44th..
13.2.202417:45BWCarmila: 2023 Annual Results
02.2.202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202419:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02.2.202417:45BWCARMILA: Information Concerning the Total Number of Voting..
16.1.202417:45BWCarmila: Resources Devoted to the Liquidity Contract as of..
08.1.202417:57BWCARMILA: Information Concerning the Total Number of Voting..
21.12.202313:00PRNUSCarisma Therapeutics to Present at the 42nd Annual J.P...
14.12.202313:00PRNUSFirst In Vivo CAR-M Lead Candidate Nominated Under..
05.12.202317:45BWCarmila : Informations relatives au nombre total de droits..
28.11.202313:00PRNUSCarisma Therapeutics Announces FDA Clearance of IND..
22.11.202313:30PRNUSCarisma Therapeutics to Participate in Evercore ISI..
10.11.202320:17BWCarmila: Termination of Liquidity Contract With BNP Paribas..
09.11.202317:45BWCARMILA : Informations relatives au nombre total de droits..
09.11.202314:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202313:42EDGAR2Form 8-K - Current report
09.11.202313:30PRNUSCarisma Therapeutics Reports Third Quarter 2023 Financial..
31.10.202314:25PRNUSCarisma Presents Pre-Clinical Proof of Concept for in vivo..
25.10.202315:11PRNUSCarisma to Present First Results From in vivo CAR-M..
20.10.202317:47BWCarmila: Financial Information as of 30 September 2023
02.10.202318:35BWCarmila : Emission d’un emprunt obligataire de 500 millions..
02.10.202317:45BWCARMILA : Informations relatives au nombre total de droits..
05.9.202314:30PRNUSCarisma Therapeutics to Present at Upcoming Investor..
01.9.202317:45BWCARMILA : Informations relatives au nombre total de droits..
01.9.202315:05EDGAR2Form 8-K - Current report
01.9.202314:30PRNUSCarisma Announces Latest Data from Phase 1 Clinical Trial of..